Specific t cell subpopulation for diagnosis, prognosis, risk prediction and treatment of ibd

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8ααlow phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8ααlow T lymphocytes, from a blood sample and without needing to assess their F. prau specificity. T lymphocytes with a CD4+ CD8ααlow CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prau is particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Keywords: Flow Cytometry, Immunoassay, Diagnostic, Risk Prediction, Treatment Response, Prognosis in IBD, Inflamatory Bowel Disease, Crohn's Disease
Patent Application number: EP18305677.9
Publications:
Gastroenterology. 2018 Jul 5. pii: S0016-5085(18)34720-6. doi: 10.1053/j.gastro.2018.06.078.

Reference:

BIO17114-D1

Business Developper
contact
Sylvestre CHEA
Sylvestre CHEA
Business Development Manager
Patent filling date: 2018-06-01

You might also be interested in